Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Based on iTunes & Spotify (publisher stats).
- Per-Episode Audience
Est. listeners per new episode within ~30 days
10,001 - 25,000 - Monthly Reach
Unique listeners across all episodes (30 days)
25,001 - 75,000 - Active Followers
Loyal subscribers who consistently listen
15,001 - 40,000
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 10 epsHosts
Recent guests
Recent episodes
Amantadine (Symmetrel)
Apr 8, 2026
17m 01s
VMAT2 Inhibitors: Valbenazine (Ingrezza) and Deutetrabenazine (Austedo)
Mar 21, 2026
17m 19s
A DSM Conversation with Dr. Allen Frances
Feb 25, 2026
55m 50s
Topiramate (Topamax)
Jan 28, 2026
15m 19s
What Makes Something a Psychiatric Illness? Featuring Dr. Mark Ruffalo, MSW, DPsa
Jan 14, 2026
54m 32s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 4/8/26 |  Amantadine (Symmetrel)✨ | Amantadinepsychiatry+3 | — | AmantadineSymmetrel | — | AmantadineSymmetrel+3 | — | 17m 01s | |
| 3/21/26 | VMAT2 Inhibitors: Valbenazine (Ingrezza) and Deutetrabenazine (Austedo)✨ | tardive dyskinesiaVMAT2 inhibitors+3 | — | Valbenazine (Ingrezza)Deutetrabenazine (Austedo)+3 | — | tardive dyskinesiaVMAT2 inhibitors+3 | — | 17m 19s | |
| 2/25/26 | A DSM Conversation with Dr. Allen Frances✨ | DSMPsychiatry+3 | Dr. Allen Frances | DSM IIIDSM IV | — | DSMAllen Frances+3 | — | 55m 50s | |
| 1/28/26 | Topiramate (Topamax)✨ | psychiatrymedication+3 | — | TopiramateTopamax+2 | — | TopiramateTopamax+3 | — | 15m 19s | |
| 1/14/26 | What Makes Something a Psychiatric Illness? Featuring Dr. Mark Ruffalo, MSW, DPsa✨ | psychiatric illnesspsychotherapy+3 | Dr. Mark Ruffalo | University of Central Florida College of MedicineTufts University School of Medicine+2 | — | psychiatric illnesspsychotherapy+3 | — | 54m 32s | |
| 12/31/25 | Lorazepam (Ativan)✨ | benzodiazepinepsychiatry+3 | — | LorazepamAtivan+3 | — | LorazepamAtivan+5 | — | 14m 27s | |
| 12/17/25 | The Vitamin Series: Iron Deficiency in Psychiatry✨ | iron deficiencymental health+3 | — | NCBIScienceDirect+3 | — | iron deficiencypsychiatry+4 | — | 25m 24s | |
| 12/3/25 | Nutritional Psychiatry with Dr. Laura Lachance✨ | Nutritional PsychiatryMental Health+3 | Dr. Laura Lachance | EASe-GAD trialAntidepressant Food Score+1 | — | Nutritional PsychiatryAntidepressant Food Score+4 | — | 49m 18s | |
| 11/19/25 | Stress, Culture, and Determinism with Dr. Robert Sapolsky✨ | stressculture+3 | Dr. Robert Sapolsky | Stanford UniversityInstitute of Primate Research+3 | — | stressculture+5 | — | 1h 03m 08s | |
| 11/5/25 | SSRIs Revisited: The 100th Episode✨ | SSRIsmental health+3 | — | Selective Serotonin Reuptake Inhibitors | — | SSRIsSelective Serotonin Reuptake Inhibitors+3 | — | 32m 53s |
Showing 10 of 10
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
13 placements across 10 markets.
Chart Positions
13 placements across 10 markets.